Sasaki K, Kantarjian HM, Morita K, et al. - Researchers compared results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD + ofatumumab (hyper-CVAD + ofatumumab) vs those of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD plus rituximab (hyper-CVAD + Rituximab) among patients suffering from Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). They performed a comparison between 69 patients treated with hyper-CVAD + ofatumumab vs 95 historical-control patients managed with hyper-CVAD + Rituximab. They adjusted for baseline covariates between groups, by using a propensity score analysis with inverse probability of treatment weighting. With hyper-CVAD + Rituximab and hyper-CVAD + ofatumumab, the estimated median event-free survival with stem cell transplantation (SCT) censoring was 33 and 65 months, respectively. The estimated median overall survival with SCT censoring was 52 months and not reached, respectively. Findings revealed that better outcomes were conferred by hyper-CVAD + ofatumumab in newly diagnosed Philadelphia chromosome–negative ALL cases, when compared with results of hyper-CVAD + Rituximab.